Direct Biologics

Direct Biologics is a leader in regenerative medicine, focusing on the development of next-generation bioactive products derived from stem cells. Their innovative technology centers on Extracellular Vesicle (EV) products, which are formulated from adult human mesenchymal stem/stromal cells and contain therapeutic bioactive molecules. Operating as a science-driven entity, Direct Biologics emphasizes clinical and scientific advancements in regenerative therapies through its role as a cGMP-certified manufacturer. The company prioritizes extensive research to offer biologics of high quality and safety, revolutionizing medical therapeutic approaches. Recent developments include receiving FDA clearance for a clinical trial involving ExoFlo™, a product with potential applications in complex diseases like Crohn's and COVID-19 related conditions. The company continues to focus on expanding its pipeline to address a variety of challenging medical conditions, backed by robust clinical data.